Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-06-2018 | Oculoplastics and Orbit

Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves’ orbitopathy

Authors: Kai-Chun Cheng, Yu-Jen Wu, Kai-Hung Cheng, Kai-Yuan Cheng, Kuo-Jen Chen, Wen-Chuan Wu, Po-Yen Lee, Cheng-Hsien Chang

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2018

Abstract

Purpose

This study surveyed the novel autoantigens expressed in the orbital fat tissue of patients with Graves’ orbitopathy (GO) and explored the possibility of the autoantibodies against novel autoantigens as biomarkers for GO.

Methods

We used immuno-proteomic methods to survey novel autoantigens expressed in the orbit fat tissue of GO patients and confirmed by enzyme-linked immunosorbent assay (ELISA).

Results

One protein spot (aldehyde dehydrogenase 2 (ALDH2)) revealed high reactivity with the GO serum than did the healthy control serum and was further verified by ELISA. We found that the plasma anti-ALDH2 antibody level was increased in GO patients compared to healthy control donors. In addition, anti-ALDH2 antibody level was correlated with GO activity classified by clinical activity score(r = 0.588, p < 0.001, using Pearson’s correlation).

Conclusions

These increased levels of anti-ALDH2 antibody in GO serum suggested that ALDH2 could attribute target autoantigen in GO, and anti-ALDH2 autoantibody might serve as a biomarker for GO and help to predict disease activity.

Perros P, Neoh C, Dickinson J (2009) Thyroid eye disease. BMJ 338:b560CrossRefPubMed

Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, Mourits MP (2011) Optimal management of graves orbitopathy: a multidisciplinary approach. Neth J Med 69:302–308PubMed

Bahn RS (2003) Clinical review 157: Pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88:1939–1946. https://doi.org/10.1210/jc.2002-030010 CrossRefPubMed

Garrity JA, Bahn RS (2006) Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 142:147–153. https://doi.org/10.1016/j.ajo.2006.02.047 CrossRefPubMedPubMedCentral

Gianoukakis AG, Khadavi N, Smith TJ (2008) Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid 18:953–958. https://doi.org/10.1089/thy.2007.0405 CrossRefPubMedPubMedCentral

Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 52:267–271CrossRef

Wall JR, Lahooti H (2010) Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol 61:222–227PubMed

Kubota S, Gunji K, Ackrell BA, Cochran B, Stolarski C, Wengrowicz S, Kennerdell JS, Hiromatsu Y, Wall J (1998) The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 83:443–447. https://doi.org/10.1210/jcem.83.2.4553 PubMedCrossRef

Kahaly GJ, Bang H, Berg W, Dittmar M (2005) Alpha-fodrin as a putative autoantigen in Graves’ ophthalmopathy. Clin Exp Immunol 140:166–172. https://doi.org/10.1111/j.1365-2249.2004.02750.x CrossRefPubMedPubMedCentral

10.

Hrda P, Sterzl I, Vana S, Novak Z, Matucha P, Kromminga A (2007) Endocrine orbitopathy and significance of autoantibodies against 1D protein. Cas Lek Cesk 146:273–277PubMed

11.

Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 181:4397–4405CrossRefPubMedPubMedCentral

12.

Lahooti H, Parmar KR, Wall JR (2010) Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol 4:417–425PubMedPubMedCentral

13.

Cheng KC, Huang HH, Hung CT, Chen CC, Wu WC, Suen JL, Chen KJ, Wu YJ, Chang CH (2013) Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy. Graefes Arch Clin Exp Ophthalmol 251:2777–2787. https://doi.org/10.1007/s00417-013-2446-9 CrossRefPubMed

14.

Lu CM, Lin JJ, Huang HH, Ko YC, Hsu JL, Chen JC, Din ZH, Wu YJ (2014) A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis. BMC Cancer 14:363. https://doi.org/10.1186/1471-2407-14-363 CrossRefPubMedPubMedCentral

15.

Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 47:9–14CrossRef

16.

Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velazquez-Villoria A, Galofre JC (2015) Graves’ Ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015:249125. https://doi.org/10.1155/2015/249125 CrossRefPubMedPubMedCentral

17.

Prabhakar BS, Bahn RS, Smith TJ (2003) Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev 24:802–835. https://doi.org/10.1210/er.2002-0020 CrossRefPubMed

18.

Douglas RS, Gupta S (2011) The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 22:385–390. https://doi.org/10.1097/ICU.0b013e3283499446 CrossRefPubMedPubMedCentral

19.

Marchitti SA, Brocker C, Stagos D, Vasiliou V (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697–720. https://doi.org/10.1517/17425255.4.6.697 CrossRefPubMedPubMedCentral

20.

Greenfield NJ, Pietruszko R (1977) Two aldehyde dehydrogenases from human liver. Isolation via affinity chromatography and characterization of the isozymes. Biochim Biophys Acta 483:35–45CrossRefPubMed

21.

Crabb DW, Matsumoto M, Chang D, You M (2004) Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc 63:49–63CrossRefPubMed

22.

Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW, Vasiliou V (2011) Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 5:283–303CrossRefPubMedPubMedCentral

23.

Edassery SL, Shatavi SV, Kunkel JP, Hauer C, Brucker C, Penumatsa K, Yu Y, Dias JA, Luborsky JL (2010) Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril 94:2636–2641. https://doi.org/10.1016/j.fertnstert.2010.04.012 CrossRefPubMedPubMedCentral

24.

Kruit PJ, van der Gaag R, Broersma L, Kijlstra A (1986) Autoimmunity against corneal antigens. I. Isolation of a soluble 54 Kd corneal epithelium antigen. Curr Eye Res 5:313–320CrossRefPubMed

25.

Verhagen C, Mor F, Kipp JB, de Vos AF, van der Gaag R, Cohen IR (1999) Experimental autoimmune keratitis induced in rats by anti-cornea T-cell lines. Invest Ophthalmol Vis Sci 40:2191–2198PubMed

26.

Chen CH, Ferreira JC, Gross ER, Mochly-Rosen D (2014) Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev 94:1–34. https://doi.org/10.1152/physrev.00017.2013 CrossRefPubMedPubMedCentral

27.

Matsuse H, Shimoda T, Fukushima C, Mitsuta K, Kawano T, Tomari S, Saeki S, Kondoh Y, Machida I, Obase Y, Asai S, Kohno S (2001) Screening for acetaldehyde dehydrogenase 2 genotype in alcohol-induced asthma by using the ethanol patch test. J Allergy Clin Immunol 108:715–719CrossRefPubMed

28.

Saravanan P, Dayan CM (2001) Thyroid autoantibodies. Endocrinol Metab Clin N Am 30:315–337 viiiCrossRef

29.

Swain M, Swain T, Mohanty BK (2005) Autoimmune thyroid disorders-an update. Indian J Clin Biochem 20:9–17. https://doi.org/10.1007/bf02893034 CrossRefPubMedPubMedCentral

Title: Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves’ orbitopathy
Authors: Kai-Chun Cheng
Yu-Jen Wu
Kai-Hung Cheng
Kai-Yuan Cheng
Kuo-Jen Chen
Wen-Chuan Wu
Po-Yen Lee
Cheng-Hsien Chang
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3894-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves’ orbitopathy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Venous beading in two or more quadrants might not be a sensitive grading criterion for severe nonproliferative diabetic retinopathy

OCT Angiography OCT Angiography (2017) by Chow, de Oliveira et al., 190 pp., 161 illustrations, €89.99/$99.99 Hardback ISBN: 9781626234734 Thieme Publishers New York/Stuttgart

The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma

Concerns of anophthalmic patients—a comparison between cryolite glass and polymethyl methacrylate prosthetic eye wearers

Mitochondrial A3243G mutation results in corneal endothelial polymegathism

Treated retinal breaks: clinical course and outcomes